65,437 trials
Fatty Liver, Nonalcoholic · NAFLD · Nonalcoholic Fatty Liver Disease
Primary: Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF — -2.918; -4.829; -1.962 Change in percentage of liver fat — p=0.199
Neoplasms · Chemotherapy-induced Nausea and Vomiting
Primary: Symptom Severity Change Over Time — 4.13; 3.81 score on a scale — p=0.083
Smoking Cessation
Primary: Rates of Prolonged Smoking Abstinence — 11; 7 Participants
Carcinoma, Transitional Cell
Primary: Objective Response Rate (ORR) - Central Assessment — 19.5; 21.6; 19.4; 23.8 percentage of participants — p==0.6991
Breast Cancer
Primary: Overall Response Rate — 1 Participants
Subjects Requiring Revision Breast Augmentation Surgery
Primary: Reoperation Rate (Per Implanted Breast) for the Presenting Condition at 12 Months. — 0; 0 Implanted breasts
Bronchopulmonary Dysplasia
Primary: Safety as Determined by Adverse Events — 123; 29; 100; 49 Events
Autism Spectrum Disorder
Primary: Positive and Negative Predictive Value of ASD Dx in Relation to Clinician Diagnostic Evaluation — 80.8; 98.3 percent
Ependymoma · Anaplastic Ependymoma
Primary: Percentage of Participants That Have Progressive Free Survival (PFS) After 1 Year — 76.4 Percentage of participants
Renal Cell Carcinoma
Primary: Disease-free Survival (DFS) as Assessed by the Investigator — NA; NA Months — p=0.0010
Benign Breast Neoplasm · Ductal Breast Carcinoma In Situ · Invasive Breast Carcinoma
Primary: Normal Breast Tissue Expression of Tumor Necrosis Factor Alpha (TNF-alpha) Levels — 0.26; 0.08; 0.06; 0.16 Log Transformed Relative ExpressionLevel — p=.50
Presbyopia
Primary: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3 — 8.1; 30.7…
Human Papillomavirus · Human Immunodeficiency Virus · Hepatitis C
Primary: Percentage of Participants Who Are Screened for All Conditions — 25.18; 8.16; 32.63; 15.79 Percentage of participants
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
Tumor
Primary: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞) of Sitravatinib — 2524.7; 2892.6 h*ng/mL